S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SRPT Sarepta Therapeutics Inc New

124.09

2.50 (2.06%)

After Hours

Last Updated: 15:30:00

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics Inc New News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 31 December 2024 (2 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Monday 30 December 2024 (3 days ago) • Edgar (US Regulatory)

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Wednesday 18 December 2024 (2 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Monday 16 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 5 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 29 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Friday 29 November 2024 (1 month ago) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Friday 29 November 2024 (1 month ago) • Business Wire

Form 8-K - Current report
Tuesday 26 November 2024 (1 month ago) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
Tuesday 26 November 2024 (1 month ago) • Business Wire

More Sarepta Therapeutics Inc New News Articles

Riza Lecci Fundo De Inve...

Societe Generale Effekten

Target Maturity Sept 202...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions